BioSpace News Archive

Klebsiella pneumoniae infections are usually hospital acquired and patients with compromised defense mechanisms are more prone to these infections.

Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the second fiscal quarter of 2020 to be in the range of $201 million to $202 million, an increase of approximately 86% - 87% over the prior year quarter.

The impact of malaria is serious and getting worse throughout the world.

Cellectis - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on Cellectis’ development activities, and thus, announces his retirement from Calyxt’s Board of Directors, effective immediately.

Santen Pharmaceutical Co., Ltd. (hereinafter, Santen) today announced that the United States Food and Drug Administration (FDA) has accepted the Premarket Approval (PMA) application for DE-128 (MicroShunt) for review.

MyoKardia, Inc. (Nasdaq: MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year. “Denelle is

Vafidemstat reduces aggression in the three psychiatric disorders studied Patients with Borderline Personality Disorder show a more relevant improvement The company will shortly start a Phase IIb trial in this indication

A new study by researchers at Hospital for Special Surgery in New York City reveals that symptomatic lower back pain resolved in 82% of patients after total hip arthroplasty and identifies which patients are more likely to have their back pain resolved.

40,000 of Beckman Coulter’s new Access SARS-CoV-2 IgG Antibody tests already received by New York City through Lenco Labs

InMode Ltd. (Nasdaq: INMD) (“InMode”), a leading global provider of innovative medical technologies, is pleased to announce that it has received clearance from the China National Medical Products Administration NMPA - (previously known as CFDA) for two proprietary InMode radiofrequency platforms - the InMode RF platform and the InMode